Anaplastic and poorly differentiated thyroid carcinomas: genetic evidence of high-grade transformation from differentiated thyroid carcinoma

J Pathol Clin Res. 2024 Mar;10(2):e356. doi: 10.1002/cjp2.356.

Abstract

Anaplastic thyroid carcinoma (ATC) is the most advanced and aggressive thyroid cancer, and poorly differentiated thyroid carcinoma (PDTC) lacks anaplastic histology but has lost architectural and cytologic differentiation. Only a few studies have focused on the genetic relationship between the two advanced carcinomas and coexisting differentiated thyroid carcinomas (DTCs). In the present study, we investigated clinicopathologic features and genetic profiles in 57 ATC and PDTC samples, among which 33 cases had concomitant DTC components or DTC history. We performed immunohistochemistry for BRAF V600E, p53, and PD-L1 expression, Sanger sequencing for TERT promoter and RAS mutations, and fluorescence in situ hybridization for ALK and RET rearrangements. We found that ATCs and PDTCs shared similar gene alterations to their coexisting DTCs, and most DTCs were aggressive subtypes harboring frequent TERT promoter mutations. A significantly higher proportion of ATCs expressed p53 and PD-L1, and a lower proportion expressed PAX-8 and TTF-1, than the coexisting DTCs. Our findings provide more reliable evidence that ATCs and PDTCs are derived from DTCs.

Keywords: ALK; BRAF; RAS; RET; TERT promoter; anaplastic thyroid carcinoma; differentiated thyroid carcinoma; genetic alteration; immunohistochemistry; poorly differentiated thyroid carcinoma.

MeSH terms

  • Adenocarcinoma*
  • B7-H1 Antigen
  • Ehlers-Danlos Syndrome*
  • Humans
  • In Situ Hybridization, Fluorescence
  • Proline / analogs & derivatives*
  • Thiocarbamates*
  • Thyroid Neoplasms* / genetics
  • Tumor Suppressor Protein p53 / genetics

Substances

  • B7-H1 Antigen
  • prolinedithiocarbamate
  • Tumor Suppressor Protein p53
  • Proline
  • Thiocarbamates

Supplementary concepts

  • Ehlers-Danlos Syndrome, musculocontractural type 1